MedWatch

Analyst: Bose hearing aid exit reflects market complexity

If Bose believed it could achieve great success on the hearing aid market, the firm wouldn’t be dropping its business making said devices, says Sydbank analyst Søren Løntoft Hansen.

Søren Løntoft Hansen, senior equity analyst at Sydbank | Photo: sydbank / pr

US-based Bose is apparently pulling the plug on its health division, under which the audio firm had been working on a hearing aid targeting the upcoming over-the-counter (OTC) sales channel in the US, news media The Boston Globe writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs